Better Therapeutics
San Francisco
About Better Therapeutics
Better Therapeutics discovers, develops, and commercializes prescription digital therapeutics for the treatment of cardiovascular and metabolic diseases. They use clinically-validated, FDA-regulated software to change the behaviors that cause these diseases to aid in quality of life, reducing the need for medications, and lowering costs. Their products deliver digital behavioral therapy that integrates neuroscience, lifestyle medicine, and explainable AI into a physician-prescribed mobile medical app and uses patient-generated data to inform clinical decision-making and improve treatment outcomes. Their current product pipeline includes therapeutic candidates for the treatment of type 2 diabetes, hypertension, and dyslipidemia.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $150.5M
- Funding stage: M&A
- Last round: Post-IPO Equity (Jan 2024)
- Ticker: nasdaq:BTTX
- Website: bettertx.com
- Phone: (415) 887-2311
Industries & Categories
Artificial Intelligence (AI), Biotechnology, mHealth, Neuroscience, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/better-therapeutics-52891 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.